Geoffrey T. Gibney, MD

Where You Are:
Geoffrey T. Gibney, MD

Assistant Member

Office  (813) 745-8482

Education And Training
  • Clinical Fellow, Yale University/Yale Cancer Center, 2011 - Hematology/Medical Oncology
  • Resident, Boston University Medical Center, 2008 - Internal Medicine
  • MD, University of Connecticut School of Medicine, 2005
  • BS, Tufts University, 2000 - Biochemistry


  • Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R. Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. J Clin Oncol. 2014 Nov;32(33):3697-3704. Pubmedid: 25287827.
  • Rebecca VW, Alicea GM, Paraiso KH, Lawrence H, Gibney GT, Smalley KS. Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res. 2014 Nov;27(6):1154-1158. Pubmedid: 25130256.
  • Fedorenko IV, Fang B, Munko AC, Gibney GT, Koomen JM, Smalley KS. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. Proteomics. 2014 Oct. Pubmedid: 25339196.
  • Fedorenko IV, Fang B, Koomen JM, Gibney GT, Smalley KS. Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma. Melanoma Res. 2014 Oct;24(5):448-453. Pubmedid: 24950457.
  • Sondak VK, Gibney GT. Indications and options for systemic therapy in melanoma. Surg Clin N Am. 2014 Oct;94(5):1049-58, viii. Pubmedid: 25245967.
  • Fedorenko IV, Gibney GT, Sondak VK, Smalley KS. Beyond BRAF: where next for melanoma therapy?. Brit J Cancer. 2014 Sep. Pubmedid: 25180764.
  • Rebecca VW, Wood ER, Fedorenko IV, Paraiso KH, Haarberg HE, Chen Y, Xiang Y, Sarnaik A, Gibney GT, Sondak VK, Koomen JM, Smalley KS. Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. Mol Cell Proteomics. 2014 Jul;13(7):1844-1854. Pubmedid: 24760959.
  • Sondak VK, Gibney GT. Surgical management of melanoma. Hematol Oncol Clin North Am. 2014 Jun;28(3):455-470. Pubmedid: 24880941.
  • Rebecca VW, Massaro RR, Fedorenko IV, Sondak VK, Anderson AR, Kim E, Amavaradi RK, Maria-Engler SS, Messina JL, Gibney GT, Kudchadkar RR, Smalley KS. Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigment Cell Melanoma Res. 2014 May;27(3):465-478. Pubmedid: 24490764.
  • Sondak VK, Gibney GT. Setting the bar for adjuvant treatment of melanoma. Lancet Oncol. 2014 May;15(6):547-548. Pubmedid: 24745697.
  • Sloot S, Fedorenko IV, Smalley KS, Gibney GT. Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?. Expert Opin Pharmaco. 2014 Apr;15(5):589-592. Pubmedid: 24456413.
  • Forsyth PA, Krishna N, Lawn S, Valadez JG, Qu X, Fenstermacher DA, Fournier M, Potthast L, Chinnaiyan P, Gibney GT, Zeinieh M, Barker PA, Carter BD, Cooper MK, Kenchappa RS. p75 neurotrophin receptor cleavage by α- and γ-secretases is required for neurotrophin-mediated proliferation of brain tumor-initiating cells. J Biol Chem. 2014 Mar;289(12):8067-8085. Pubmedid: 24519935. Pmcid: PMC3961639.
  • Kudchadkar R, Gibney G, Sondak VK. Integrating molecular biomarkers into current clinical management in melanoma. Methods Mol Biol. 2014;1102:27-42. Pubmedid: 24258972.
  • Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013 Dec;31(34):4311-4318. Pubmedid: 24145345. Pmcid: PMC3837092.
  • Weber JL, Smalley KS, Sondak VK, Gibney GT. Conjunctival Melanomas Harbor BRAF and NRAS Mutations--Letter. Clin Cancer Res. 2013 Nov;19(22):6329-6330. Pubmedid: 24166902.
  • Kenchappa RS, Tran N, Rao NG, Smalley KS, Gibney GT, Sondak VK, Forsyth PA. Novel treatments for melanoma brain metastases. Cancer Control. 2013 Oct;20(4):298-306. Pubmedid: 24077406.
  • Zager JS, Sarnaik AA, Gibney GT, Kudchadkar RR. Recent advances in the treatment of melanoma. Cancer Control. 2013 Oct;20(4):244-245. Pubmedid: 24077400.
  • Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KS. Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol. 2013 Jul;10(7):390-399. Pubmedid: 23712190. Pmcid: PMC3983565.
  • Gibney GT, Sondak VK. Has targeted therapy for melanoma made chemotherapy obsolete?. Lancet Oncol. 2013 Jul;14(8):676-677. Pubmedid: 23816289.
  • Fedorenko IV, Gibney GT, Smalley KS. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene. 2013 Jun;32(25):3009-3018. Pubmedid: 23069660. Pmcid: PMC3978385.
  • Lo RS, Ribas A, Long GV, Ballotti R, Berger M, Willy H, Gibney GT, Bosenberg M, Bernstein E, Villanueva J, Smalley KS. Meeting report from the Society for Melanoma Research 2012 Congress, Hollywood, California. Pigment Cell Melanoma Res. 2013 Apr;26(4):E1-E7. Pubmedid: 23551976.
  • Gibney GT, Zager JS. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Expert Opin Drug Metab Toxicol. 2013 Apr;9(7):893-899. Pubmedid: 23621583.
  • Gibney GT, Smalley KS. An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance. Cancer Discov. 2013 Mar;3(3):260-263. Pubmedid: 23475878. Pmcid: PMC3595124.
  • Gibney GT, Weber JS. Expanding targeted therapy to NRAS-mutated melanoma. Lancet Oncol. 2013 Mar;14(3):186-188. Pubmedid: 23414591.
  • Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 2013 Feb;24(2):343-349. Pubmedid: 23022995. Pmcid: PMC3551486.
  • Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, Kudchadkar R, Zager J, Gibney G, Sondak VK, Weber J, Mulé JJ, Sarnaik AA. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother. 2012 Oct;35(8):615-620. Pubmedid: 22996367.
  • Gibney GT, Forsyth PA, Sondak VK. Melanoma in the brain: biology and therapeutic options. Melanoma Res. 2012 Jun;22(3):177-183. Pubmedid: 22495668.
  • Gibney GT, Sondak VK. Extending the reach of BRAF-targeted cancer therapy. Lancet. 2012 May;379(9829):1858-1859. Pubmedid: 22608322.
  • Verhovsek M, So CC, O'Shea T, Gibney GT, Ma ES, Steinberg MH, Chui DH. Is HbA(2) level a reliable diagnostic measurement for β-thalassemia trait in people with iron deficiency?. Am J Hematol. 2012 Jan;87(1):114-116. Pubmedid: 22038702.
  • Gibney GT, Panhuysen CI, So JC, Ma ES, Ha SY, Li CK, Lee AC, Li CK, Yuen HL, Lau YL, Johnson DM, Farrell JJ, Bisbee AB, Farrer LA, Steinberg MH, Chan LC, Chui DH. Variation and heritability of Hb F and F-cells among beta-thalassemia heterozygotes in Hong Kong. Am J Hematol. 2008 Jun;83(6):458-464. Pubmedid: 18266208.
  • Hong SS, Gibney GT, Esquilin M, Yu J, Xia Y. Effect of protein kinases on lactate dehydrogenase activity in cortical neurons during hypoxia. Brain Res. 2004 May;1009(1-2):195-202. Pubmedid: 15120597.
  • Zhang J, Gibney GT, Zhao P, Xia Y. Neuroprotective role of delta-opioid receptors in cortical neurons. Am J Physiol Cell Physiol. 2002 Jun;282(6):C1225-C1234. Pubmedid: 11997236.
  • Gibney GT, Zhang JH, Douglas RM, Haddad GG, Xia Y. Na(+)/Ca(2+) exchanger expression in the developing rat cortex. Neuroscience. 2002;112(1):65-73. Pubmedid: 12044472.
  • Zhang JH, Gibney GT, Xia Y. Effect of prolonged hypoxia on Na+ channel mRNA subtypes in the developing rat cortex. Brain Res Mol Brain Res. 2001 Jul;91(1-2):154-158. Pubmedid: 11457503.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions